UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 100

Sortiert nach

Biomimetic Synthesis of (−)-Longithorone A

Journal of the American Chemical Society, 2002-02, Vol.124 (5), p.773-775

2002

Volltextzugriff (PDF)

Association of respiratory failure with inhibition of NaV1.6 in the phrenic nerve

Channels (Austin, Tex.), 2022-12, Vol.16 (1), p.230-243

2022

Volltextzugriff (PDF)

3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts

Bioorganic & medicinal chemistry letters, 2010-05, Vol.20 (10), p.3129-3133

2010

Volltextzugriff (PDF)

Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia

Journal of medicinal chemistry, 2023-01, Vol.66 (2), p.1157-1171

2023

Volltextzugriff (PDF)

Synthesis of Cyclooctenones Using Intramolecular Hydroacylation

Journal of the American Chemical Society, 2000-12, Vol.122 (50), p.12610-12611

2000

Volltextzugriff (PDF)

Invention of MK-7845, a SARS-CoV‑2 3CL Protease Inhibitor Employing a Novel Difluorinated Glutamine Mimic

Journal of medicinal chemistry, 2024-03, Vol.67 (5), p.3935-3958

2024

Volltextzugriff (PDF)

Discovery of selective, orally bioavailable, N-linked arylsulfonamide Nav1.7 inhibitors with pain efficacy in mice

Bioorganic & medicinal chemistry letters, 2017-05, Vol.27 (10), p.2087-2093

2017

Volltextzugriff (PDF)

Benzoxazolinone aryl sulfonamides as potent, selective Nav1.7 inhibitors with in vivo efficacy in a preclinical pain model

Bioorganic & medicinal chemistry letters, 2017-06, Vol.27 (12), p.2683-2688

2017

Volltextzugriff (PDF)

Synthesis of (-)-Longithorone A: Using Organic Synthesis to Probe a Proposed Biosynthesis

Proceedings of the National Academy of Sciences - PNAS, 2004-08, Vol.101 (33), p.12036-12041

2004

Volltextzugriff (PDF)

Discovery of 3-Substituted Aminocyclopentanes as Potent and Orally Bioavailable NR2B Subtype-Selective NMDA Antagonists

ACS chemical neuroscience, 2011-07, Vol.2 (7), p.352-362

2011

Volltextzugriff (PDF)

The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors

Current cancer drug targets, 2008-02, Vol.8 (1), p.7

2008

Volltextzugriff (PDF)

Discovery of Arylsulfonamide Nav1.7 Inhibitors: IVIVC, MPO Methods, and Optimization of Selectivity Profile

ACS medicinal chemistry letters, 2021-06, Vol.12 (6), p.1038-1049

2021

Volltextzugriff (PDF)

Discovery of Arylsulfonamide Na v 1.7 Inhibitors: IVIVC, MPO Methods, and Optimization of Selectivity Profile

ACS medicinal chemistry letters, 2021-06, Vol.12 (6), p.1038-1049

2021

Volltextzugriff (PDF)

Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors

Current topics in medicinal chemistry, 2007-07, Vol.7 (14), p.1349

2007

Volltextzugriff (PDF)

Benzoxazolinone aryl sulfonamides as potent, selective Na v 1.7 inhibitors with in vivo efficacy in a preclinical pain model

Bioorganic & medicinal chemistry letters, 2017-06, Vol.27 (12), p.2683-2688

2017

Volltextzugriff (PDF)

Discovery of selective, orally bioavailable, N-linked arylsulfonamide Na v 1.7 inhibitors with pain efficacy in mice

Bioorganic & medicinal chemistry letters, 2017-05, Vol.27 (10), p.2087-2093

2017

Volltextzugriff (PDF)

Discovery of 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as positive allosteric modulators of metabotropic glutamate subtype-2 (mGlu2) receptors with efficacy in a preclinical model of psychosis

Bioorganic & medicinal chemistry letters, 2016-02, Vol.26 (4), p.1260-1264

2016

Volltextzugriff (PDF)

Recent advances in the development of NR2B subtype-selective NMDA receptor antagonists

Current topics in medicinal chemistry, 2006-04, Vol.6 (7), p.697

2006

Volltextzugriff (PDF)

Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI

ACS medicinal chemistry letters, 2016-03, Vol.7 (3), p.312-317

2016

Volltextzugriff (PDF)

Subtype-selective noncompetitive modulators of metabotropic glutamate receptor subtype 1 (mGluR1)

Current topics in medicinal chemistry, 2005-08, Vol.5 (9), p.859

Layton, Mark E

2005

Volltextzugriff (PDF)

Synthesis of (+)-CP-263,114

Journal of the American Chemical Society, 2000-08, Vol.122 (30), p.7424-7425

2000

Volltextzugriff (PDF)

Stereospecific Synthesis of the CP-263,114 Core Structure

Journal of the American Chemical Society, 1998-10, Vol.120 (41), p.10784-10785

1998

Volltextzugriff (PDF)

ChemInform Abstract: Synthesis of Cyclooctenones Using Intramolecular Hydroacylation

ChemInform, 2001-04, Vol.32 (15), p.no-no

2001

Volltextzugriff (PDF)

ChemInform Abstract: Synthesis of (+)-CP-263,114

ChemInform, 2000-11, Vol.31 (46), p.no-no

2000

Volltextzugriff (PDF)

1 – 25 von 100

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(94)
Mit Volltextzugriff
(88)

Publikationsform

Sprache

Englisch
(100)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Biomimetic Synthesis of (−)-Longithorone A

Association of respiratory failure with inhibition of NaV1.6 in the phrenic nerve

3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts

Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia

Synthesis of Cyclooctenones Using Intramolecular Hydroacylation

Invention of MK-7845, a SARS-CoV‑2 3CL Protease Inhibitor Employing a Novel Difluorinated Glutamine Mimic

Discovery of selective, orally bioavailable, N-linked arylsulfonamide Nav1.7 inhibitors with pain efficacy in mice

Benzoxazolinone aryl sulfonamides as potent, selective Nav1.7 inhibitors with in vivo efficacy in a preclinical pain model

Synthesis of (-)-Longithorone A: Using Organic Synthesis to Probe a Proposed Biosynthesis

Discovery of 3-Substituted Aminocyclopentanes as Potent and Orally Bioavailable NR2B Subtype-Selective NMDA Antagonists

The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors

Discovery of Arylsulfonamide Nav1.7 Inhibitors: IVIVC, MPO Methods, and Optimization of Selectivity Profile

Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Biological and Pharmacological Profiling

Discovery of Arylsulfonamide Na v 1.7 Inhibitors: IVIVC, MPO Methods, and Optimization of Selectivity Profile

Recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors

Benzoxazolinone aryl sulfonamides as potent, selective Na v 1.7 inhibitors with in vivo efficacy in a preclinical pain model

Discovery of selective, orally bioavailable, N-linked arylsulfonamide Na v 1.7 inhibitors with pain efficacy in mice

Discovery of 5-aryl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-ones as positive allosteric modulators of metabotropic glutamate subtype-2 (mGlu2) receptors with efficacy in a preclinical model of psychosis

Recent advances in the development of NR2B subtype-selective NMDA receptor antagonists

Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI

Subtype-selective noncompetitive modulators of metabotropic glutamate receptor subtype 1 (mGluR1)

Synthesis of (+)-CP-263,114

Stereospecific Synthesis of the CP-263,114 Core Structure

ChemInform Abstract: Synthesis of Cyclooctenones Using Intramolecular Hydroacylation

ChemInform Abstract: Synthesis of (+)-CP-263,114

Suchergebnisse filtern